The Role and Mechanism of Gut Microbiota in Pulmonary Arterial Hypertension

Area of Science:

• Cardiovascular Research
• Microbiome Science
• Pulmonary Hypertension

Background:

• Pulmonary arterial hypertension (PAH) is a severe vascular disease impacting the lungs and heart.
• The gut microbiota (GM) and its metabolites are increasingly recognized for their role in cardiovascular conditions.
• Evidence links GM alterations to the development and progression of PAH.

Purpose of the Study:

• To explore the intricate relationship between gut microbiota, its metabolites, and pulmonary arterial hypertension.
• To elucidate the mechanisms by which GM dysbiosis influences PAH pathogenesis.
• To highlight the potential of microbiome-targeted therapies for PAH treatment.

Main Methods:

• Review of current literature on gut microbiota, metabolites, and PAH.
• Analysis of molecular mechanisms linking gut dysbiosis to pulmonary vascular inflammation and remodeling.
• Examination of emerging therapeutic strategies involving probiotics and fecal microbiota transplantation.

Main Results:

• Gut microbiota dysbiosis increases intestinal permeability, leading to bacterial translocation and inflammation.
• Altered gut metabolites (e.g., reduced SCFAs, increased TMAO, elevated serotonin) promote pulmonary vascular changes.
• GM alterations contribute to endothelial-mesenchymal transition and exacerbate PAH.

Conclusions:

• The gut microbiota and its metabolites are significant factors in PAH development and progression.
• Targeting the gut microbiome presents a promising avenue for novel diagnostic, preventive, and therapeutic approaches to PAH.
• Further research into microbiome-based interventions could revolutionize PAH management.